Improving treatment adherence to antihypertensive therapy: The role of single-pill combinations

Expert Opinion on Pharmacotherapy

Volumn 13, Issue 3, 2012, Pages 345-355

  Bangalore, Sripal ^a   Ley, Ludwin ^b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Adherence; Antihypertensives; Compliance; Hypertension control; Persistence; Single pill combination therapy

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; THIAZIDE DIURETIC AGENT;

ANKLE EDEMA; COLD LIMB; COMBINATION CHEMOTHERAPY; COUGHING; DIZZINESS; DRUG DOSAGE FORM; DRUG TOLERABILITY; FATIGUE; FLUSHING; HUMAN; HYPERTENSION; IMPOTENCE; MONOTHERAPY; MUSCLE CRAMP; NAUSEA; PATIENT COMPLIANCE; POLYPHARMACY; REVIEW; SIDE EFFECT;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION; MEDICATION ADHERENCE; RISK ASSESSMENT; RISK FACTORS; TABLETS; TREATMENT OUTCOME;

EID: 84856287359     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2012.652086     Document Type: Review

References (71)

1. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006;13:e442
2. Chobhanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and treatment of high blood pressure (The JNC 7 report). JAMA 2003;89:2560-72 (Pubitemid 37430158)
3. Blood Pressure Lowering Treatment Trialists Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003;362:1527-35
4. Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension 1988 - 2008. JAMA 2010;303:2043-50.
5. Ostchega Y, Yoon SS, Hughes J, Louis T. Hypertension awareness, treatment and control - continued disparities in adults: United States, 2005 - 2006. NCHS Data Brief 2008;3:1-8
6. Ong KL, Cheung BMY, Man BY, et al. Pravalence, awareness, treatment, and control of hypertension among United States adults 1999 - 2004. Hypertension 2007;49:69-75 (Pubitemid 46360343)
7. Kotseva K, Wood D, De Backer G, et al. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet 2009;373:929-40
8. Mazzaglia G, Ambrosioni E, Alacqua M, et al. Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients. Circulation 2009;120:1598-605
9. Dragomir A, Cote R, Roy L, et al. Impact of adherence to antihypertensive agents on clinical outcomes and hospitalization costs. Med Care 2010;48:418-25
10. Elliott WJ. Improving outcomes in hypertensive patients: focus on adherence and persistence with antihypertensive therapy. J Clin Hypertens (Greenwich) 2009;11:376-82
11. Erdine S. Compliance with the treatment of hypertension: the potential of combination therapy. J Clin Hypertens (Greenwich) 2010;12:40-6
12. Fung V, Huang J, Brand R, et al. Hypertension treatment in a medicare population: adherence and systolic blood pressure control. Clin Ther 2007;29:972-84 (Pubitemid 47223429)
13. Maron DJ, Boden WE, O'Rourke RA, et al. COURAGE Trial Research Group. Intensive multifactorial intervention for stable coronary artery disease: optimal medical therapy in the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial. J Am Coll Cardiol 2010;55:1348-58
14. Benner JS, Chapman RH, Petrilla AA, et al. Association between prescription burden and medication adherence in patients initiating antihypertensive and lipid-lowering therapy. Am J Health Syst Pharm 2009;66:1471-7
15. Schroeder K, Fahey T, Ebrahim S. How can we improve adherence to blood pressure-lowering medication in ambulatory care? Systematic review of randomised controlled trials. Arch Intern Med 2004;164:722-32 (Pubitemid 38478694)
16. Conn VS, Hafdahl AR, Cooper PS, et al. Interventions to improve medication adherence among older adults: meta-analysis of adherence outcomes among randomised controlled trials. Gerontologist 2009;49:447-62
17. Feldman RD, Zou GY, Vandervoort MK, et al. A simplified approach to the treatment of uncomplicated hypertension: a cluster randomized, controlled trial. Hypertension 2009;53:646-53
18. Mancia G, De Backer G, Dominiczak A, et al. for The task force for the management of arterial hypertension of the European Society of Hypertension, The task force for the management of arterial hypertension of the European Society of Cardiology. 2007 Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007;28:1462-536
19. Brown MJ. Renin: friend or foe? Heart 2007;93:1026-33 (Pubitemid 47310975)
20. Messerli FH, Bangalore S, Ruschitzka F. Angiotensin receptor blockers: baseline therapy in hypertension? Eur Heart J 2009;30:2427-30
21. Yusuf S, Teo KK, Pogue J, et al. for the ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-59 (Pubitemid 351522739)
22. Katragadda S, Arora RR. Role of angiotensin-converting enzyme inhibitors in vascular modulation: beyond the hypertensive effects. Am J Ther 2010;17:e11-23
23. Gupta M, Honos GN, Velazquez EJ, et al. Evidence for the efficacy of ARBs across the cardiovascular continuum. Curr Med Res Opin 2010;26:1203-18.
24. Brenner BM, Cooper ME, de ZD, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345(12):861-9
25. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345(12):851-60
26. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003 (Pubitemid 34286536)
27. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-97
28. Bangalore S, Kumar S, Kjeldsen SE, et al. Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials. Lancet Oncol 2011;12:65-82
29. ARB Trialists Collaboration. Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals. J Hypertens 2011;29:623-35
30. Bangalore S, Parkar S, Messerli FH. Long-acting calcium antagonists in patients with coronary artery disease: a meta-analysis. Am J Med 2009;122:356-65
31. Bangalore S, Sawhney S, Messerli FH. Relation of beta-blocker-induced heart rate lowering and cardioprotection in hypertension. J Am Coll Cardiol 2008;52:1482-9
32. Bangalore S, Wild D, Parkar S, et al. Beta-blockers for primary prevention of heart failure in patients with hypertension insights from a meta-analysis. J Am Coll Cardiol 2008;52:1062-72
33. Messerli FH, Bangalore S, Julius S. Risk/benefit assessment of beta-blockers and diuretics precludes their use for first-line therapy in hypertension. Circulation 2008;117:2706-15
34. Bangalore S, Kamalakkannan G, Messerli FH. Beta-blockers: no longer an option for uncomplicated hypertension. Curr Cardiol Rep 2007;9:441-6 (Pubitemid 350081414)
35. Bangalore S, Messerli FH, Kostis JB, Pepine CJ. Cardiovascular protection using beta-blockers: a critical review of the evidence. J Am Coll Cardiol 2007;50:563-72 (Pubitemid 47202065)
36. Schumacher H, Mancia G. The safety profile of telmisartan as monotherapy or combined with hydrochlorothiazide: a retrospective analysis of 50 studies. Blood Press 2008;17(Suppl 1):32-40
37. Corrao G, Zambon A, Parodi A, et al. Discontinuation of and changes in drug therapy for hypertension among newly-treated patients: a population-based study in Italy. J Hypertens 2008;26:819-24 (Pubitemid 351354932)
38. Smith DH. Comparison of angiotensin II type 1 receptor antagonists in the treatment of essential hypertension. Drugs 2008;68(9):1207-25 (Pubitemid 351822111)
39. Bangalore S, Kumar S, Messerli FH. Angiotensin-converting enzyme inhibitor associated cough: deceptive information from the Physicians' Desk Reference. Am J Med 2010;123:1016-30
40. Kronish IM, Woodward M, Sergie Z, et al. Meta-analysis: impact of drug class on adherence to antihypertensives. Circulation 2011;123:1611-21
41. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003;326:1427
42. Gradman AH, Basile JN, Carter BL, et al. ASH position article: combination therapy in hypertension. J Am Soc Hypertens 2010;4:90-8
43. Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009;27:2121-58
44. Flack JM, Sica DA, Bakris G, et al. Management of High Blood Pressure in Blacks. An update of the International society on hypertension in blacks consensus statement. Hypertension 2010;56:780-800
45. Littlejohn TW III, Majul CR, Olvera R, et al. Results of treatment with telmisartan-amlodipine in hypertensive patients. J Clin Hypertens (Greenwich) 2009;11:207-13
46. Littlejohn TW III, Majul CR, Olvera R, et al. Telmisartan plus amlodipine in patients with moderate or severe hypertension: results from a subgroup analysis of a randomized, placebo-controlled, parallel-group, 4 - 4 factorial study. Postgrad Med 2009;121:5-14
47. Chrysant SG, Melino M, Karki S, et al. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clin Ther 2008;30:587-604 (Pubitemid 351680489)
48. Philipp T, Smith TR, Glazer R, et al. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin Ther 2007;29:563-80 (Pubitemid 47028551)
49. Tedesco MA, Natale F, Calabro R. Effects of monotherapy and combination therapy on blood pressure control and target organ damage: a randomized prospective intervention study in a large population of hypertensive patients. J Clin Hypertens 2006;8:634-41
50. Wald DS, Law M, Morris JK, et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med 2009;122:290-300
51. White WB, Littlejohn TW, Majul CR, et al. Effects of telmisartan and amlodipine in combination on ambulatory blood pressure in stages 1-2 hypertension. Blood Press Monit 2010;15:205-12
52. NICE Guidelines. Available from: http://guidance.nice.org.uk/CG127 [Accessed August 2011
53. Makani H, Bangalore S, Romero J, et al. Effect of renin-angiotensin system blockade on calcium channel blocker-associated peripheral edema. Am J Med 2011;124:128-35
54. Fogari R, Malamani G, Zoppi A, et al. Effect on the development of ankle edema of adding delapril to manidipine in patients with mild to moderate essential hypertension: a three-way crossover study. Clin Ther 2007;29:413-18 (Pubitemid 46907281)
55. Fogari R, Zoppi A, Derosa G, et al. Effect of valsartan addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients. J Hum Hypertens 2007;21:220-4
56. Fogari R, Zoppi A, Maffioli P, Lazzari P. Effect of telmisartan addition to amlodipine on ankle edema development in treating hypertensive patients. Expert Opin Pharmacother 2011;12(16):2441-8
57. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007;120:713-19 (Pubitemid 47176510)
58. Dickson M, Plauschinat CA. Compliance with antihypertensive therapy in the elderly. Am J Cardiovasc Drugs 2008;8:45-50
59. Gerbino PP, Shoheiber O. Adherence patterns among patients treated with fixed-dose combination versus separate antihypertensive agents. Am J Health Syst Pharm 2007;64:1279-83 (Pubitemid 47216196)
60. Zeng F, Patel BV, Andrews L, et al. Adherence and persistence of single-pill ARB/CCB combination therapy compared to multiple-pill ARB/CCB regimens. Curr Med Res Opin 2010;26:2877-87
61. Schmieder RE. The role of fixed-dose combination therapy with drugs that target the renin-angiotensin system in the hypertension paradigm. Clin Exp Hypertens 2010;32:35-42
62. Chrysant SG. The role of angiotensin receptor blocker and calcium channel blocker combination therapy in treating hypertension: focus on recent studies. Am J Cardiovasc Drugs 2010;10:315-20
63. Neldam S, Lang M, Jones R, on behalf of the TEAMSTA-5 Investigators. Telmisartan and amlodipine single-pill combinations versus amlodipine monotherapy for superior blood pressure lowering and improved tolerability in patients with uncontrolled hypertension: results of the TEAMSTA-5 study. J Clin Hypertens 2011;13(7):459-66
64. Neldam S, Edwards C, Jones R, on behalf of the TEAMSTA-10 Investigators. Long-term efficacy and safety profile of single-pill combinations of telmisartan/amlodipine in patients not controlled on amlodipine 10 mg: open-label follow-up of teamsta-10: Pp.27.90. J Hypertens 2010;28:e474
65. Littlejohn, TW III, Chrysant SG, Webster D, et al. Efficacy of telmisartan in combination with amlodipine in obese hypertensive patients: sub-analysis from a factorial design study. J Clin Hypertens 2009;11(Suppl A):A158
66. Littlejohn T, Ruilope LM, Raskin P, et al. Telmisartan in combination with amlodipine provides a highly effective and well tolerated treatment option for hypertensive patients with diabetes: sub-analysis from a factorial design study. J Hypertens 2009;27(Suppl 4);S275
67. Chrysant SG, Lee J, Melino M, et al. Efficacy and tolerability of amlodipine plus olmesartan medoxomil in patients with difficult-to-treat hypertension. J Hum Hypertens 2010;24:730-8
68. Neutel JM, Mancia G, Black HR, et al. Single-pill combination of telmisartan 80 mg/amlodipine 10 mg provides superior blood pressure reductions in patients with severe hypertension: TEAMSTA Severe HTN Study [abstract]. J Clin Hypertens 2010;12(Suppl7):537
69. Jamerson K, Bakris GL, Dahlof B, et al. ACCOMPLISH Investigators. Exceptional early blood pressure control rates: the ACCOMPLISH trial. Blood Press 2007;16:80-6 (Pubitemid 47050368)
70. Jamerson K, Weber MA, Bakris GL, et al. ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008;359:2417-28
71. Bakris GL, Sarafidis PA, Weir MR, et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet 2010;375:1173-81